Fig. 5From: Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & IIDecreasing trend of D.Dimer level in the treated group within 5 days of starting treatment. Mean reduction of D-dimer in treated group was 42% (P < 0.05)Back to article page